Blast Crisis Market

The blast crisis market has been comprehensively analyzed in IMARC's new report titled "Blast Crisis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Blast crisis is an aggressive and critical phase of chronic myeloid leukemia (CML), a type of blood cancer. During this phase, the bone marrow, which is responsible for producing blood cells, experiences a sudden and uncontrollable increase in immature, abnormal white blood cells known as blasts. These blasts crowd out normal blood cells, leading to a host of severe symptoms and complications. The indications of the condition include fatigue, weakness, fever, an enlarged spleen and liver, easy bruising or bleeding, and an increased susceptibility to infections due to the compromised immune system. Individuals suffering from the illness may also experience bone pain and weight loss. The diagnosis of blast crisis involves a thorough examination of the patient's medical history, physical symptoms, and laboratory tests, including blood counts and a bone marrow biopsy. Distinguishing this disease from the chronic phase of CML or various other similar conditions is crucial for determining appropriate treatment strategies.

The increasing incidences of genomic instability, leading to genetic mutations and chromosomal abnormalities, are primarily driving the blast crisis market. In addition to this, the inflating utilization of targeted therapies, including tyrosine kinase inhibitors, nucleoside analogs, and monoclonal antibodies, to curb the progression of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of hematopoietic stem cell transplantation procedure, which involves the transplantation of healthy stem cells to replenish the depleted, aberrant cell population in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of supportive therapies, such as granulocyte colony-stimulating factors, red blood cell and platelet transfusions, antibiotics, etc., since they help in mitigating infection risks, anemia, and various other treatment-related side effects, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of precision medicine, wherein treatments are customized based on the individual patient's genetic makeup and disease characteristics, is also augmenting the market growth. Furthermore, the escalating application of CAR-T cell therapy, in which T cells are modified to recognize and combat cancer cells effectively, thereby enhancing the quality of life, is expected to drive the blast crisis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the blast crisis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for blast crisis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the blast crisis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the blast crisis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the blast crisis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current blast crisis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the blast crisis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the blast crisis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the blast crisis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of blast crisis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of blast crisis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of blast crisis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with blast crisis across the seven major markets?
• What is the size of the blast crisis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of blast crisis?
• What will be the growth rate of patients across the seven major markets?
   

Blast Crisis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for blast crisis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the blast crisis market?
• What are the key regulatory events related to the blast crisis market?
• What is the structure of clinical trial landscape by status related to the blast crisis market?
• What is the structure of clinical trial landscape by phase related to the blast crisis market?
• What is the structure of clinical trial landscape by route of administration related to the blast crisis market?